SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Growth Hormone SecretagoguesResearch peptide

Tesamorelin

A long-acting GHRH analog originally approved for HIV-associated lipodystrophy and visceral fat reduction.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Tesamorelin is a stabilized analog of GHRH with extended half-life, FDA-approved in some regions for reducing visceral adipose tissue in HIV lipodystrophy.

Source
  • Pharmaceutical manufacturing
Forms
  • Subcutaneous injection

Mechanism of action

Binds the GHRH receptor on the pituitary to stimulate endogenous GH release, with downstream reductions in visceral fat.

Pathways
  • · GHRH-R signaling
  • · Lipolysis in visceral adipose
Receptors
  • · GHRH receptor
Hormones
  • · Growth hormone
  • · IGF-1

How it acts on the body

Tesamorelin is essentially native GHRH with a trans-3-hexenoyl group attached to its N-terminus, which protects it from degradation by dipeptidyl peptidase IV. The result is a longer-lasting GHRH signal that produces sustained, modestly elevated GH pulses across the day.

Its claim to fame is selective visceral fat loss. Visceral adipocytes express more GH receptors than subcutaneous adipocytes, so a chronically raised GH tone preferentially drives lipolysis in deep abdominal fat depots — including liver fat. This is why tesamorelin tends to reduce VAT and improve triglycerides while having a relatively small effect on subcutaneous body weight.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

Growth hormoneIncreases
Sustained increase in pulse amplitude and overnight area-under-the-curve.
IGF-1Increases
Significant rise — monitoring is standard practice during therapy.
Insulin sensitivityDecreases
Mild reductions can occur; glucose monitoring is recommended.
Free fatty acidsIncreases
Rises with lipolysis from visceral fat.
TriglyceridesDecreases
Often improve as visceral and hepatic fat fall.

Effects on the body

Decreases
Visceral adipose tissue
Increases
IGF-1 levels
Supports
Lipid profile improvements

Organ system effects

Liver

May reduce intrahepatic fat in some populations.

Endocrine

Strong, sustained GH/IGF-1 elevation.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Targeted visceral fat reduction
  • Improved triglycerides in studied populations
  • May improve cognition in some older adults

Potential side effects

Common
  • · Injection-site reactions
  • · Arthralgia
  • · Peripheral edema
Rare
  • · Carpal tunnel symptoms
  • · Hyperglycemia
Serious
  • · Reduced insulin sensitivity over long-term use

Drug interactions

Insulin / antidiabetics
Monitor glucose; dosing may need adjustment.
moderate
Corticosteroids
Blunt GH response.
moderate

Pairing context

Often combined with
  • Resistance training
    Synergistic for body-composition outcomes.
Avoid combining with
  • Active malignancy
    GH/IGF-1 elevation is generally avoided.
  • Pregnancy
    Not studied; avoid.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.